Previous 10 | Next 10 |
PTC Therapeutics Provides Corporate Update and Reports Third Quarter Financial Results PR Newswire – Third quarter 2023 total revenues of $197 million and remain on target for 2023 revenue guidance – – PTC strengthened its financial position fo...
PTC Therapeutics Inc. (PTCT) is expected to report $-0.85 for Q3 2023
2023-10-19 19:02:30 ET A new royalty deal was the fuel that powered biotech PTC Therapeutics (NASDAQ: PTCT) stock to a 15% gain on Thursday. That arrangement, which covers PTC's spinal muscular atrophy (SMA) treatment Evrysdi, features a hefty upfront payment that could also bring i...
2023-10-19 08:31:42 ET More on PTC, Roche, etc. Recursion Pharmaceuticals: Wet Lab Meets Silicon, A Tale Of Two Bottom Lines Roche: Positive Readouts From Pipeline Roche: 2023 Should Mark The Bottom Roche slips after in-line Q3 sales Roche in pact wit...
PTC Therapeutics Announces Evrysdi® Royalty Agreement with Royalty Pharma for Up To $1.5 Billion PR Newswire - PTC to receive $1B in upfront cash for approximately 67% of outstanding royalties, with option for additional $500M - - Financing pro...
PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2023 Financial Results PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2023 Financial Results PR Newswire SOUTH PLAINFIELD, N.J. , Oct. 16, 2023 /PRNewswire/ -- ...
2023-10-06 10:52:41 ET More on PTC Therapeutics PTC Therapeutics: Struggling Still But Potential Remains PTC Therapeutics, Inc. (PTCT) Q2 2023 Earnings Call Transcript PTC Technologies announces workforce reduction impacting 25% of the company Citi lowers PTC...
2023-09-28 16:57:30 ET More on PTC Therapeutics PTC Therapeutics: Struggling Still But Potential Remains PTC Therapeutics, Inc. (PTCT) Q2 2023 Earnings Call Transcript Citi lowers PTC Therapeutics to neutral amid uncertainty for DMD drug Larimar, Design highe...
PTC Announces Further Strategic Prioritization and Associated Reduction in Workforce PR Newswire - Translarna CHMP opinion re-examination request to be submitted - SOUTH PLAINFIELD, N.J. , Sept. 28, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDA...
2023-09-20 11:55:57 ET More on Health Care Sector: Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR Health Care Select Sector SPDR ETF declares quarterly distribution of $0.5395 BofA clients were net buyers of U.S. equities for a fifth consecutiv...
News, Short Squeeze, Breakout and More Instantly...
PTC Therapeutics Inc. Company Name:
PTCT Stock Symbol:
NASDAQ Market:
PTC Therapeutics Inc. Website:
PTC Therapeutics Announces Sepiapterin NDA Submission to FDA PR Newswire WARREN, N.J. , July 30, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the sepiapterin NDA to the U.S. FDA. The NDA submission is for the t...
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results PR Newswire WARREN, N.J. , July 25, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to r...
2024-07-12 10:00:03 ET Jeffrey Hung from Morgan Stanley issued a price target of $32.00 for PTCT on 2024-07-12 08:15:00. The adjusted price target was set to $32.00. At the time of the announcement, PTCT was trading at $33.2. The overall price target consensus is at $43....